Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TetraLogic nets $53.5mm through initial public offering

Executive Summary

TetraLogic Pharmaceuticals Corp. (small-molecule cancer and infectious disease therapeutics) netted $53.5mm through its initial public offering of 8.2mm shares (including the overallotment) at $7 (much lower than the anticipated range of $13-15). Existing investors including Pfizer Inc. and affiliates, Amgen Inc., and company executives (the chairman, president and CEO, and CFO) purchased 4.6mm of the IPO shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies